Your browser doesn't support javascript.
Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-analysis.
Aggarwal, Ashutosh Nath; Agarwal, Ritesh; Dhooria, Sahajal; Prasad, Kuruswamy Thurai; Sehgal, Inderpaul Singh; Muthu, Valliappan.
  • Aggarwal AN; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Agarwal R; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Dhooria S; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Prasad KT; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Sehgal IS; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Muthu V; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
PLoS One ; 16(10): e0259006, 2021.
Article in English | MEDLINE | ID: covidwho-1480463
ABSTRACT

OBJECTIVE:

The proportion of COVID-19 patients having active pulmonary tuberculosis, and its impact on COVID-19 related patient outcomes, is not clear. We conducted this systematic review to evaluate the proportion of patients with active pulmonary tuberculosis among COVID-19 patients, and to assess if comorbid pulmonary tuberculosis worsens clinical outcomes in these patients.

METHODS:

We queried the PubMed and Embase databases for studies providing data on (a) proportion of COVID-19 patients with active pulmonary tuberculosis or (b) severe disease, hospitalization, or mortality among COVID-19 patients with and without active pulmonary tuberculosis. We calculated the proportion of tuberculosis patients, and the relative risk (RR) for each reported outcome of interest. We used random-effects models to summarize our data.

RESULTS:

We retrieved 3,375 citations, and included 43 studies, in our review. The pooled estimate for proportion of active pulmonary tuberculosis was 1.07% (95% CI 0.81%-1.36%). COVID-19 patients with tuberculosis had a higher risk of mortality (summary RR 1.93, 95% CI 1.56-2.39, from 17 studies) and for severe COVID-19 disease (summary RR 1.46, 95% CI 1.05-2.02, from 20 studies), but not for hospitalization (summary RR 1.86, 95% CI 0.91-3.81, from four studies), as compared to COVID-19 patients without tuberculosis.

CONCLUSION:

Active pulmonary tuberculosis is relatively common among COVID-19 patients and increases the risk of severe COVID-19 and COVID-19-related mortality.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis, Pulmonary / SARS-CoV-2 / COVID-19 / Hospitalization Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0259006

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis, Pulmonary / SARS-CoV-2 / COVID-19 / Hospitalization Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0259006